REGISTER
Zejing Biopharma Launches Fourth In-House Product
Zejing Biopharma has won approval for recombinant human thyrotropin beta for use in follow-up evaluation after thyroidectomy in differentiated thyroid cancer. The product is described as China’s first approved innovative therapy for precise postsurgical assessment in this setting and showed strong concordance and tolerability in Phase III testing.

On January 8, Zejing Biopharma announced that its independently developed recombinant human thyrotropin beta for injection, formerly known as recombinant human thyroid-stimulating hormone for injection and marketed as Zesuning, was approved in China. It is indicated as an adjunct in the follow-up of patients with differentiated thyroid cancer after total or near-total thyroidectomy for serum thyroglobulin (Tg) testing, with or without radioactive iodine-131 whole-body scintigraphy (WBS).

According to the company press release, recombinant human thyrotropin beta for injection is the fourth independently developed product launched by Zejing Biopharma and also the first innovative product approved in China for precision postsurgical assessment in differentiated thyroid cancer, filling a market gap in this field.

Endogenous human thyroid-stimulating hormone belongs to the glycoprotein hormone family. It is mainly expressed in and secreted from the pituitary into the bloodstream and binds to hTSHR protein expressed on thyroid cells and highly differentiated thyroid cancer cells, thereby stimulating iodine uptake and organification as well as synthesis and release of thyroglobulin, triiodothyronine, and thyroxine. Recombinant human TSH has an amino acid sequence identical to that of natural human TSH.

Activation of thyroid cells by recombinant human TSH increases radioactive iodine uptake, enabling scanning detection or radioiodine-mediated killing of thyroid cancer cells. It also causes thyroid cells to release thyroglobulin, which serves as a tumor marker for thyroid cancer in blood samples.

Results from the Phase III clinical study ZGTSH004 showed that among evaluable participants, the concordance between WBS diagnostic results after administration of recombinant human thyrotropin beta and those after thyroid hormone withdrawal, as assessed by an independent review committee, was 88.2%. Among participants who were thyroglobulin antibody-negative and evaluable for thyroglobulin at both stages, concordance of the two-stage Tg assessment was 90.4% using 1 ng/mL as the cutoff.

In terms of safety, compared with thyroid hormone withdrawal, administration of recombinant human thyrotropin beta significantly reduced hypothyroid symptoms such as eyelid edema, weight gain, and cold intolerance, while emotional state scores also improved significantly, effectively avoiding the decline in quality of life caused by thyroid hormone withdrawal.

In June 2025, Zejing Biopharma entered into a cooperation agreement with Merck KGaA, Germany, authorizing it to act as the exclusive marketing service provider for human thyrotropin beta in mainland China, excluding Hong Kong SAR, Macao SAR, and Taiwan.

0
0
Loading